Իսրայել - անգլերեն - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 20 mg - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

Իսրայել - անգլերեն - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 40 mg - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

Իսրայել - անգլերեն - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 60 mg - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

Իսրայել - անգլերեն - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 80 mg - ziprasidone - • schizophrenia. treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • bipolar mania. ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features.• bipolar disorder. maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

roerig - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg in 1 ml - geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] . acute treatment of agitation in schizophrenia - geodon intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need intram

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

astellas pharma co. limited - solifenacin succinate - oral suspension - 1 milligram(s)/millilitre - drugs for urinary frequency and incontinence; solifenacin - urologicals, drugs for urinary frequency and incontinence - symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

tya pharmaceuticals - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg in 1 ml - geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other an tipsychotic drugs [ )]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ ] see

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

a-s medication solutions - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)]

Հարավաֆրիկյան Հանրապետություն - անգլերեն - South African Health Products Regulatory Authority (SAHPRA)

viatris healthcare (pty) ltd - injection - see ingredients - each 1,0 ml solution contains ziprasidone 20,0 mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

pfizer limited - ziprasidone hydrochloride monohydrate - oral suspension - 10